**Supplementary Tables**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1**. Characteristics of participants excluded from the analysis (due to missing date of admission or symptom onset, date of admission or symptom onset after 4thJune 2020, missing HIV status, or unconfirmed HIV-positive status) relative to those included | | | | | | | | | | | | | | | |
| Characteristic | | Excluded | | | | | | | |  | Included | | | | |
| Missing date  of admission or symptom onset  n=2,694 | | Symptom onset  >4th June 2020  n=303 | | Missing HIV status  n=2,742 | | Unable to confirm  HIV-positive status  n=63 | | HIV-positive  n=115 | | | HIV-negative  n=47,424 | |
| Age, median years (IQR) | | 73 (55, 83) | | 75 (61, 86) | | 73 (61, 85) | | 75 (62, 83) | | 55 (49, 61) | | | 74 (60, 84) | |
| Age group,  n (%) | <40 | 145/1,330 | (10.9) | 28/301 | (9.3) | 151/2,662 | (5.7) | 2/61 | (3.3) | 7/113 | (6.2) | 2,574/46,882 | | (5.5) |
| 40-49 | 106/1,330 | (8.0) | 19/301 | (6.3) | 176/2,662 | (6.6) | 4/61 | (6.6) | 26/113 | (23.0) | 3,242/46,882 | | (6.9) |
| 50-59 | 157/1,330 | (11.8) | 26/301 | (8.6) | 321/2,662 | (12.1) | 6/61 | (9.8) | 47/113 | (41.6) | 5,940/46,882 | | (12.7) |
| 60-69 | 172/1,330 | (12.9) | 46/301 | (15.3) | 377/2,662 | (14.2) | 11/61 | (18.0) | 23/113 | (20.4) | 7,266/46,882 | | (15.5) |
| ≥70 | 750/1,330 | (56.4) | 182/301 | (60.5) | 1,637/2,662 | (61.5) | 38/61 | (62.3) | 10/113 | (8.9) | 27,860/46,882 | | (59.4) |
| Female, n (%) | | 579/1,278 | (45.3) | 155/303 | (51.2) | 1,160/2,685 | (43.2) | 28/62 | (45.2) | 39/114 | (34.2) | 20,280/47,258 | | (42.9) |
| Ethnicity,  n (%) | White | 866/1,020 | (84.3) | 237/280 | (84.6) | 1,567/2,030 | (77.2) | 50/59 | (84.8) | 44/106 | (41.5) | 35,501/42,163 | | (84.2) |
| Black | 25/1,020 | (2.6) | 7/280 | (2.5) | 69/2,030 | (3.4) | 4/59 | (6.8) | 48/106 | (45.3) | 1,473/42,163 | | (3.5) |
| Asian | 64/1,020 | (6.5) | 21/280 | (7.5) | 228/2,030 | (11.2) | 2/59 | (3.4) | 1/106 | (0.9) | 2,247/42,163 | | (5.3) |
| Other | 65/1,020 | (6.7) | 15/280 | (5.4) | 166/2,030 | (8.2) | 3/59 | (5.1) | 13/106 | (12.3) | 2,942/42,163 | | (7.0) |
| Outcomes,  n (%) | Critical care | 15/205 | (7.3) | 42/260 | (16.2) | 125/983 | (12.7) | 11/62 | (17.7) | 35/115 | (30.4) | 6,699/46,452 | | (14.4) |
| Invasive ventilation | 11/194 | (5.7) | 11/242 | (4.6) | 33/545 | (6.1) | 2/59 | (3.4) | 19/109 | (17.4) | 3,997/45,209 | | (8.8) |
| Died | 102/303 | (33.7) | 12/79 | (15.2) | 541/1,096 | (49.4) | 20/56 | (35.7) | 26/104 | (25.0) | 14,541/42,975 | | (33.8) |

Abbreviations: IQR, Interquartile range.

**Supplementary Table 2.** Regional distribution of study participants   
with HIV compared to the total United Kingdom population of people   
accessing HIV care in 2018a

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Region | Study participants with HIV, n (%) | | People receiving HIV  care in 2018, n (%) | |
| Total number | 115 | (100) | 96,135 | (100) |
| London | 34 | (29.6) | 36.689 | (38.2) |
| Midlands & East of England | 31 | (27.0) | 19,387 | (20.2) |
| North of England | 24 | (20.9) | 16,500 | (17.2) |
| South of England | 23 | (20.0) | 15,426 | (16.0) |
| Scotland | 3 | (2.6) | 4,799 | (5.0) |
| Wales | 0 | (0) | 2,204 | (2.3) |
| Northern Ireland | 0 | (0) | 1,130 | (1.2) |

aData from Public Health England26

**Supplementary Table 3.** Binomial logistic regression analysis of the likelihood of admission to critical care according to HIV status

|  |  |  |  |
| --- | --- | --- | --- |
| HIV-positive versus HIV-negative | Odds ratio | 95% CI | P value |
| Unadjusted | 2.60 | 1.74-3.87 | <0.001 |
| Adjusted for sex | 2.43 | 1.62-3.64 | <0.001 |
| Adjusted for age | 1.53 | 1.01-2.31 | 0.05 |
| Adjusted for sex, age, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, and 10 comorbiditiesa | 1.13 | 0.72-1.75 | 0.59 |

aThe final model adjusted for the following comorbidities: chronic cardiac disease, chronic pulmonary disease, chronic renal disease, diabetes, obesity, chronic neurological disorder, dementia, liver disease, malignancy, and chronic haematological disease. Abbreviations: CI, Confidence interval.

**Supplementary Table 4.** COVID-19 outcomes according to HIV status and follow-up timea

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | HIV-positive n=115 | | HIV-negative  n=47,424 | |
| Outcome at 14 days | | | | |
| Death | 24 | (20.9) | 11,550 | (24.4) |
| Discharged alive | 59 | (51.3) | 19,232 | (40.6) |
| Remaining in hospital | 17 | (14.8) | 11,293 | (23.8) |
| Transfer to other facility | 4 | (3.5) | 1,251 | (2.6) |
| Unknown outcome | 11 | (9.6) | 4,098 | (8.6) |
| Outcome at 28 days | | | | |
| Death | 26 | (22.6) | 13,955 | (29.4) |
| Discharged alive | 67 | (58.3) | 23,575 | (49.7) |
| Remaining in hospital | 7 | (6.1) | 3,708 | (7.8) |
| Transfer to other facility | 4 | (3.5) | 1,797 | (3.8) |
| Unknown outcome | 11 | (9.6) | 4,389 | (9.3) |
| Outcome at last known follow up | | | | |
| Death | 26 | (22.6) | 14,541 | (30.7) |
| Discharged alive | 72 | (62.6) | 25,349 | (53.5) |
| Transfer to other facility | 4 | (3.5) | 2,099 | (4.4) |
| Remaining in hospital | 2 | (1.7) | 986 | (2.1) |
| Unknown outcome | 11 | (9.6) | 4,449 | (9.4) |

**a**Unknown outcome: an outcome had not been recorded at the time of analysis

**Supplementary Table 5.** Sensitivity analyses investigating the association between HIV status and 28-day mortality

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Analysis |  | Hazard or  Odds ratio | 95% CI | P-value |
| 1 | Model 1: Primary Cox proportional hazard model of day-28 mortality, HIV-positive versus HIV-negative people, adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, and 10 comorbidities (as shown in Table 4)a | HR 1.49 | 0.99-2.26 | 0.06 |
| 2 | Model 1 also adjusted for hypoxia/on oxygen at presentation (as shown in Table 4) | HR 1.63 | 1.07-2.48 | 0.02 |
| 3 | Model 1 with follow-up censored on the day of discharge for those discharged before day 28 | HR 1.53 | 1.01-2.33 | 0.05 |
| 4 | Model 1 including definite hospital acquired COVID-19b | HR 1.48 | 0.98-2.24 | 0.06 |
| 5 | Model 1 using symptom onset date as baseline date for all patients | HR 1.50 | 0.97-2.33 | 0.07 |
| 6 | Model 1 excluding PWH lacking a record of ART | HR 1.43 | 0.91-2.26 | 0.11 |
| 7 | Model 1 including propensity score for HIV status | HR 1.39 | 0.93-2.09 | 0.11 |
| 8 | Model 1 including propensity score for HIV status and hypoxia / on oxygen at presentation | HR 1.51 | 1.00-2.28 | 0.05 |
| 9 | Binary logistic regression model of day-14 mortality, HIV-positive people versus HIV-negative people, adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, and 10 comorbiditiesa | OR 1.77 | 1.06-2.95 | 0.03 |

aThe model adjusted for the following comorbidities: chronic cardiac disease, chronic pulmonary disease, chronic renal disease, diabetes, obesity, chronic neurological disorder, dementia. liver disease, malignancy, and chronic haematological disease. bBased on onset of symptoms >14 days after admission. Abbreviations: CI, Confidence interval; HR, Hazard ratio; PWH, people with HIV; ART, Antiretroviral therapy; OR, Odds ratio.

**Supplementary Table 6.** Characteristics of patients with HIV, stratified by outcome at day 28

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Characteristic | | Died n=26 | | Alive n=89 | | P-value |
| Age, median years (IQR) | | 58 | (52, 72) | 54.5 | (49, 60) | 0.07 |
| Age group,  n (%) | <40 | 1/24 | (4.2) | 6/89 | (6.7) | 0.06 |
| 40-49 | 4/24 | (16.7) | 22/89 | (24.7) |
| 50-59 | 10/24 | (41.7) | 37/89 | (41.6) |
| 60-69 | 3/24 | (12.5) | 20/89 | (22.5) |
| ≥70 | 6/24 | (25.0) | 4/89 | (4.5) |
| Female, n (%) | | 7/25 | (28.0) | 32/89 | (36.0) | 0.46 |
| Ethnicity,  n (%) | White | 9/24 | (37.5) | 35/82 | (42.7) | 0.52 |
| Black | 10/24 | (41.7) | 38/82 | (46.3) |
| Asian | 0/24 | (0) | 1/82 | (1.2) |
| Other | 5/24 | (20.8) | 8/82 | (9.8) |
| Smoking,  n (%) | Never | 15/23 | (65.2) | 47/66 | (71.2) | 0.52 |
| Former | 6/23 | (26.1) | 10/66 | (15.2) |
| Current | 2/23 | (8.7) | 9/66 | (13.6) |
| ART recorded, n (%) |  | 22/26 | (84.6) | 83/89 | (93.3) | 0.17 |
| Comorbidities,  n (%) | None | 4/26 | (15.4) | 26/89 | (29.2) | 0.54 |
| 1 | 12/26 | (46.2) | 32/89 | (36.0) |  |
| 2 | 7/26 | (26.9) | 22/89 | (24.7) |  |
| 3 | 3/26 | (11.5) | 9/89 | (10.1) |  |
| Type of comorbidities, n (%) | Chronic cardiac disease | 5/26 | (19.2) | 15/85 | (17.7) | 1.0 |
| Chronic pulmonary diseasea | 0/26 | (0) | 12/88 | (13.6) | 0.05 |
| Asthma | 3/25 | (12.0) | 8/85 | (9.4) | 0.71 |
| Chronic renal disease | 3/25 | (12.0) | 16/85 | (18.8) | 0.56 |
| Diabetes, no complications | 4/26 | (15.4) | 12/84 | (14.3) | 1.0 |
| Diabetes, with complications | 5/26 | (19.2) | 3/84 | (3.6) | 0.02 |
| Obesity | 8/24 | (33.3) | 11/81 | (13.6) | 0.03 |
| Chronic neurological disorder | 2/26 | (7.7) | 5/84 | (6.0) | 0.67 |
| Dementia | 0/25 | (0) | 3/86 | (3.5) | 1.0 |
| Mild liver disease | 0/26 | (0) | 3/85 | (3.5) | 1.0 |
| Moderate/severe liver disease | 1/26 | (3.9) | 5/85 | (5.9) | 1.0 |
| Malignancy | 0/26 | (0) | 3/85 | (3.5) | 1.0 |
| Chronic haematological disease | 1/26 | (3.9) | 3/85 | (3.5) | 1.0 |
| Rheumatological disease | 2/26 | (7.7) | 4/85 | (4.7) | 0.62 |
| Malnutrition | 1/24 | (4.2) | 4/81 | (4.9) | 1.0 |
| Presenting symptoms,  n (%) | Fever | 22/25 | (88.0) | 72/89 | (80.9) | 0.41 |
| Myalgia | 5/20 | (25.0) | 21/76 | (27.6) | 1.0 |
| Headache | 3/19 | (15.8) | 15/70 | (21.4) | 0.75 |
| Cough | 22/25 | (88.0) | 66/89 | (74.2) | 0.15 |
| Dyspnoea | 20/25 | (80.0) | 64/89 | (71.9) | 0.61 |
| Chest pain | 6/21 | (28.6) | 18/80 | (22.5) | 0.56 |
| Sore throat | 1/18 | (5.6) | 12/74 | (16.2) | 0.24 |
| Wheeze | 2/21 | (9.5) | 3/73 | (4.1) | 0.33 |
| Rhinorrhoea | 1/19 | (5.3) | 2/70 | (2.8) | 0.61 |
| Diarrhoea | 8/22 | (36.4) | 17/78 | (21.8) | 0.16 |
| Nausea or vomiting | 4/22 | (18.2) | 19/75 | (25.3) | 0.49 |
| Abdominal pain | 2/21 | (9.5) | 11/75 | (14.7) | 0.54 |
| Fatigue | 9/19 | (47.4) | 31/71 | (43.7) | 0.77 |
| Symptom groupb,  n (%) | Systemic | 24/25 | (96.0) | 79/89 | (88.8) | 0.28 |
| Respiratory | 24/25 | (96.0) | 76/89 | (85.4) | 0.15 |
| Gastrointestinal | 10/23 | (43.5) | 32/80 | (40.0) | 0.77 |
| Symptom duration, median days (IQR) | | 6 | (2, 10) | 4 | (1, 9) | 0.25 |
| Symptom duration c,  n (%) | <3 days | 25/26 | (96.2) | 83/89 | (93.3) | 1.0 |
| 3-7 days | 0/26 | (0) | 1/89 | (1.1) |  |
| 8-14 days | 1/26 | (3.9) | 3/89 | (3.4) |  |
| >14 days | 0/26 | (0) | 2/89 | (2.3) |  |
| Presenting signs | Temperature, median °C (IQR) | 37.9 | (37.1, 38.6) | 37.8 | (36.9, 38.6) | 0.98 |
| Fever ≥37.8 °C, n (%) | 13/24 | (54.2) | 46/87 | (52.9) | 0.91 |
| HR, median beats/min (IQR) | 106 | (96, 120) | 93 | (80, 108) | <0.001 |
| Tachycardiad, n (%) | 16/25 | (64.0) | 35/87 | (40.2) | 0.04 |
| RR, median breaths/min (IQR) | 26 | (19, 30) | 20 | (18, 24) | 0.02 |
| Tachypnoeae, n (%) | 15/23 | (65.2) | 35/84 | (41.7) | 0.05 |
| Hypoxiaf/oxygen therapy, n (%) | 18/24 | (75.0) | 32/84 | (38.1) | 0.001 |
| Infiltrates visible on CXR, n (%) | 11/15 | (73.3) | 35/55 | (63.6) | 0.48 |
| Systolic BP, median mmHg (IQR) | 130 | (109, 142) | 129 | (118, 144) | 0.81 |
| Diastolic BP, median mmHg (IQR) | 70 | (62, 81) | 81 | (69, 89) | 0.04 |
| Laboratory parameters | Haemoglobin, median g/L (IQR) | 127 | (111, 141) | 131 | (118,146) | 0.45 |
|  | Anaemiag, n (%) | 11/24 | (45.8) | 26/77 | (33.8) | 0.28 |
|  | WBC, median count x109/L (IQR) | 7.8 | (5.5, 10.9) | 5.7 | (4.7, 8.7) | 0.02 |
|  | Lymphocytes, median count x109/L (IQR) | 0.9 | (0.7, 1.4) | 1.0 | (0.8, 1.6) | 0.58 |
|  | Lymphopeniah, n (%) | 13/25 | (52.0) | 34/77 | (44.2) | 0.49 |
|  | Platelets, median count x106/L (IQR) | 199 | (157, 252) | 200 | (147, 263) | 0.99 |
|  | Thrombocytopeniai, n (%) | 5/24 | (20.8) | 19/75 | (25.3) | 0.79 |
|  | Prothrombin time, median sec (IQR) | 14.2 | (11.8, 15.4) | 13.2 | (11.0, 15.0) | 0.49 |
|  | Creatinine, median µmol/L (IQR) | 94 | (75, 153) | 89 | (72, 132) | 0.46 |
|  | eGFRJ, median ml/min/1.73m2 (IQR) | 72 | (51, 87) | 78 | (58, 102) | 0.12 |
|  | ALT, median U/L (IQR) | 34 | (20, 44) | 27 | (18, 45) | 0.50 |
|  | ALT >40 U/L, n (%) | 7/21 | (33.3) | 19/64 | (29.7) | 0.75 |
|  | Glucose, median mmol/L (IQR) | 10.3 | (6.4, 12.3) | 6.4 | (5.8, 8.3) | 0.06 |
|  | Hyperglycaemiak, n (%) | 5/13 | (38.5) | 5/39 | (12.8) | 0.10 |
|  | C-reactive protein, median mg/L (IQR) | 203 | (103, 306) | 92 | (42, 149) | <0.001 |
| Interventions, n (%) | Oxygen therapy during admission | 21/26 | (80.8) | 51/84 | (60.7) | 0.06 |
|  | Critical care admission | 17/26 | (65.4) | 18/89 | (20.2) | <0.001 |
|  | Non-invasive ventilation | 9/24 | (37.5) | 15/83 | (18.1) | <0.001 |
|  | Invasive ventilation | 13/26 | (50.0) | 6/88 | (6.8) | <0.001 |

aExcluding asthma, bSystemic symptoms: ≥1 of fever, myalgia or headache; Respiratory symptoms: ≥1 of cough, dyspnoea, chest pain, sore throat, wheeze; Gastrointestinal symptoms: ≥1 of: Diarrhoea, nausea, vomiting or abdominal pain. cBased on the onset of symptoms relative to the date of admission, COVID-19 acquisition was classed as community (<3 days), indeterminate (3-7 days), probable hospital (8-14 days), and definite hospital (>14 days). dDefined as HR >100 beats/min. eDefined as RR >20 breaths/min. fDefined as SpO2 <94% on air. gDefined as haemoglobin <130 g/L in males and <115 g/L in females. hDefined as lymphocyte count <1.0 x109/L. iDefined as platelet count <150 x106/L. jBased on the Modification of Diet in Renal Disease (MDRD) formula where eGFR (mL/min/1.73 m²) = 175 × (Scr/88.4)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if Black ethnicity). kDefined as glucose >11 mmol/L. Abbreviations: IQR, Interquartile range; HR, Heart rate; RR, Respiratory rate; CXR, Chest X-ray; BP, Blood pressure; WBC, White blood cells; eGFR, estimated glomerular filtration rate; ALT, alanine transaminase.

**Supplementary Table 7.** Cox proportional hazard model for death at 28 days among people with HIV

|  |  |  |  |
| --- | --- | --- | --- |
| Comparison | Univariate  hazard ratio | 95% CI | P value |
| Age, per year | 1.05 | (1.01- 1.09) | 0.01 |
| Sex, male vs female | 1.53 | (0.64-3.67) | 0.34 |
| Chronic heart disease | 1.18 | (0.44-3.12) | 0.74 |
| Asthma | 1.21 | (0.36-4.04) | 0.75 |
| Diabetes | 2.29 | (1.02-5.13) | 0.05 |
| Obesity | 3.21 | (1.39-7.44) | 0.006 |
| ART recorded | 0.33 | (0.13-0.83) | 0.02 |

Abbreviation: ART, Antiretroviral therapy.